QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment

Shinde, Aishwarya; Panchal, Kanan; Patra, Parameswar; Singh, Sonali; Enakolla, Sucharitha; Paliwal, Rishi; Chaurasiya, Akash

doi:10.1208/s12249-024-02806-w

AAPS PharmSciTech

2024

DOI: 10.1208/s12249-024-02806-w

|View full text |Cite

QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment

Aishwarya Shinde,

Kanan Panchal,

Parameswar Patra

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Progressive cancer targeting by programmable aptamer‐tethered nanostructures

Mohammadi,

Zahraee,

Zibadi

et al. 2024

MedComm

View full text Add to dashboard Cite

Scientific research in recent decades has affirmed an increase in cancer incidence as a cause of death globally. Cancer can be considered a plurality of various diseases rather than a single disease, which can be a multifaceted problem. Hence, cancer therapy techniques acquired more accelerated and urgent approvals compared to other therapeutic approaches. Radiotherapy, chemotherapy, immunotherapy, and surgery have been widely adopted as routine cancer treatment strategies to suppress disease progression and metastasis. These therapeutic approaches have lengthened the longevity of countless cancer patients. Nonetheless, some inherent limitations have restricted their application, including insignificant therapeutic efficacy, toxicity, negligible targeting, non‐specific distribution, and multidrug resistance. The development of therapeutic oligomer nanoconstructs with the advantages of chemical solid‐phase synthesis, programmable design, and precise adjustment is crucial for advancing smart targeted drug nanocarriers. This review focuses on the significance of the different aptamer‐assembled nanoconstructs as multifunctional nucleic acid oligomeric nanoskeletons in efficient drug delivery. We discuss recent advancements in the design and utilization of aptamer‐tethered nanostructures to enhance the efficacy of cancer treatment. Valuably, this comprehensive review highlights self‐assembled aptamers as the exceptionally intelligent nano‐biomaterials for targeted drug delivery based on their superior stability, high specificity, excellent recoverability, inherent biocompatibility, and versatile functions.

show abstract

Progressive cancer targeting by programmable aptamer‐tethered nanostructures

Mohammadi,

Zahraee,

Zibadi

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer

Xu,

Zhou,

Yang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Pazopanib (PAZ), an oral multi-tyrosine kinase inhibitor, demonstrates promising cytostatic activities against various human cancers. However, its clinical utility is limited by substantial side effects and therapeutic resistance. We developed a nanoplatform capable of delivering PAZ for enhanced anti-breast cancer therapy. Nanometer-sized PAZ@Fe-MOF, compared to free PAZ, demonstrated increased anti-tumor therapeutic activities in both syngeneic murine 4T1 and xenograft human MDA-MB-231 breast cancer models. High-throughput single-cell RNA sequencing (scRNAseq) revealed that PAZ@Fe-MOF significantly reduced pro-tumorigenic M2-like macrophage populations at tumor sites and suppressed M2-type signaling pathways, such as ATF6-TGFBR1-SMAD3, as well as chemokines including CCL17, CCL22, and CCL24. PAZ@Fe-MOF reprogramed the inhibitory immune microenvironment and curbed tumorigenicity by blocking the polarization of M2 phenotype macrophages. This platform offers a promising and new strategy for improving the cytotoxicity of PAZ against breast cancers. It provides a method to evaluate the immunological response of tumor cells to PAZ-mediated treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

QbD Enabled Development and Evaluation of Pazopanib Loaded Nanoliposomes for PDAC Treatment

Cited by 2 publications

References 50 publications

Progressive cancer targeting by programmable aptamer‐tethered nanostructures

Progressive cancer targeting by programmable aptamer‐tethered nanostructures

Determining M2 macrophages content for the anti-tumor effects of metal-organic framework-encapsulated pazopanib nanoparticles in breast cancer

Contact Info

Product

Resources

About